menu
    • menu
    [{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Neltependocel","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aurion Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aurion Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Neltependocel","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aurion Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aurion Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Neltependocel","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aurion Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aurion Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Neltependocel","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Aurion Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aurion Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Neltependocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aurion Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aurion Biotech \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Y27632

    Menu

    Y27632

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aurion Biotech

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aurion Biotech

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neltependocel,Y27632

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aurion Biotech Launches Vyznova® in Japan for Bullous Keratopathy

                            Details : Vyznova is a combination cell therapy product (biologic/drug) comprised of neltependocel & Y-27632, being evaluated for the treatment of bullous keratopathy of the cornea.

                            Brand Name : Vyznova

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 24, 2024

                            Lead Product(s) : Neltependocel,Y27632

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aurion Biotech

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aurion Biotech

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neltependocel,Y27632

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aurion's AURN001 Gets Breakthrough and RMAT Designations

                            Details : AURN001 is a cell therapy product comprised of neltependocel. It is being evaluated in combination with Y27632 for the treatment of corneal edema secondary to corneal endothelial dysfunction.

                            Brand Name : AURN001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 19, 2024

                            Lead Product(s) : Neltependocel,Y27632

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aurion Biotech

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aurion Biotech

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neltependocel,Y27632

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aurion Biotech Announces Completion of Enrollment in Phase 1 / 2 Clinical Trial

                            Details : AURN001 is a combination cell therapy product comprised of neltependocel & Y-27632 . It is being evaluated for the treatment of corneal edema secondary to corneal endothelial dysfunction.

                            Brand Name : AURN001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 30, 2024

                            Lead Product(s) : Neltependocel,Y27632

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aurion Biotech

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aurion Biotech

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neltependocel,Y27632

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial

                            Details : AURN001 is a combination cell therapy product comprised of neltependocel & Y-27632 . It is being evaluated for the treatment of corneal edema secondary to corneal endothelial dysfunction.

                            Brand Name : AURN001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 28, 2024

                            Lead Product(s) : Neltependocel,Y27632

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aurion Biotech

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aurion Biotech

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neltependocel,Y27632

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aurion Biotech Announces First Subject Dosed in U.S. Phase 1 / 2 Clinical Trial

                            Details : AURN001 (CECs and Y-27632) is a combination cell therapy product and administered to the eye as a one-time, intracameral injection, which is investigated for the treatment of corneal edema secondary to corneal endothelial dysfunction.

                            Brand Name : AURN001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 24, 2023

                            Lead Product(s) : Neltependocel,Y27632

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth